Hasegawa, Tsukasa
Yanagitani, Noriko
Ohyanagi, Fumiyoshi
Kudo, Keita
Horiike, Atsushi
Tambo, Yuichi
Nishikawa, Shingo
Ariyasu, Ryo
Uchibori, Ken
Kitazono, Satoru
Nishio, Makoto
Article History
Received: 21 June 2020
Accepted: 22 October 2020
First Online: 7 November 2020
Compliance with ethical standards
:
: Makoto Nishio reports honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Boehringer-ingelheim, MSD, and Novartis, research funding from Novartis, Daiichi Sankyo, Taiho Pharmaceutical, Bristol-Myers Squibb, Boehringer-ingelheim, Ono Pharmaceutical, Eli Lilly, Chugai Pharmaceutical, AstraZeneca, Merck Sernon, MSD and Pfizer. Atsushi Horiike reports honoraria from Chugai Pharmaceutical and Taiho Pharmaceutical, research funding from Chugai Pharmaceutical. Noriko Yanagitani reports employment/leadership position/ advisory role of Chugai Pharmaceutical. Yuichi Tambo reports honoraria from AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical and MSD. Ken Uchibori reports employment/leadership position/ advisory role of Daiichi Sankyo. All the other authors have stated that they have no conflicts of interest.